1000393993.jpg
Which anti biotic should use in this pt..as it is operated case of bilateral evd
Reading File
Finding Sources
Finding Sources
Searching PubMed
MRSA ventriculitis external ventricular drain vancomycin
Finding Sources
Searching PubMed
MRSA bacteremia vancomycin CNS neurosurgical
Reading File
Reading File
I now have solid textbook evidence to give a complete, clinically focused answer.
Antibiotic Recommendation - MRSA Bacteremia in Post-Bilateral EVD Patient
Culture Report Summary
| Parameter | Finding |
|---|---|
| Organism | MRSA (Methicillin-resistant S. aureus) |
| Specimen | Blood |
| Ward | Neuro Surgery ICU |
| Highly Susceptible | Vancomycin, Moxifloxacin |
| Intermediate Sensitive | Ciprofloxacin, Levofloxacin, Gentamicin |
| Resistant | Penicillin, Cefoxitin, Amoxicillin-clavulanate, Erythromycin, Clindamycin, Linezolid |
Drug of Choice: VANCOMYCIN IV (First Line)
This is the clear choice given:
- Listed as Highly Susceptible on the culture
- It is the standard of care for serious MRSA infections including bacteremia, and CNS/neurosurgical infections
- It has activity across staphylococci, streptococci, and gram-positive anaerobes
Dosing:
- Vancomycin 15-20 mg/kg IV every 8-12 hours (up to 2 g per dose, adjusted for renal function)
- Use AUC-based dosing (target AUC/MIC >400) -- preferred over trough-only monitoring
- If AUC-based dosing not available: target trough levels 15-20 μg/mL for serious MRSA infections
- Duration: typically 4-6 weeks for bacteremia with an intravascular/neurosurgical source
Key Monitoring:
- Renal function (creatinine, BUN) - nephrotoxicity risk increases with troughs >20 μg/mL
- Vancomycin levels (trough or AUC)
- Avoid concomitant nephrotoxins if possible (aminoglycosides, NSAIDs)
Critical Consideration: The EVD (External Ventricular Drain)
This patient has bilateral EVDs -- a major concern because:
- Blood-borne MRSA in a neurosurgical patient with EVD in-situ carries high risk of ventriculitis / catheter-related CNS infection
- Vancomycin has poor CNS penetration when meninges are not inflamed (CSF levels are only 10-15% of serum)
- If there is any CSF pleocytosis, positive CSF culture, or clinical signs of ventriculitis (fever, altered sensorium, CSF clouding), consider:
Add intraventricular vancomycin (IVT vancomycin) directly through the EVD:
- Typical dose: 5-20 mg/day via EVD (clamped for 15-60 min after instillation)
- Recommended by IDSA/neurosurgical infection guidelines for device-related ventriculitis with MRSA
- CSF vancomycin levels should be checked if possible
Alternative / Adjunct Options
| Drug | Role | Caveat |
|---|---|---|
| Moxifloxacin (also Highly Susceptible) | Oral step-down once bacteremia cleared, good CNS penetration | Not first-line for bacteremia; use as adjunct/step-down |
| Daptomycin 6-10 mg/kg IV q24h | Alternative to vancomycin for bacteremia | Cannot be used for CNS infection (inactivated by lung surfactant/CNS lipids) |
| Ceftaroline + Vancomycin/Daptomycin | Salvage for persistent bacteremia (>3 days) | Second line only |
| Rifampicin combination | Anti-biofilm activity on EVD | Add if EVD cannot be removed; never as monotherapy |
Note: Linezolid is listed as RESISTANT on this culture - do NOT use.
Practical Management Plan
- Start Vancomycin IV immediately (weight-based dosing, renally adjusted)
- Send CSF from EVD for cell count, glucose, protein, Gram stain, and culture
- If CSF is infected/turbid: add intraventricular vancomycin via EVD
- Consider EVD change/removal if possible - device removal is the single most important intervention for catheter-related MRSA infection
- Repeat blood cultures at 48-72 hours to document clearance
- Infectious Diseases consult strongly recommended given the complexity (bilateral EVD + MRSA bacteremia)
- Echocardiography (TTE/TEE) to rule out endocarditis given sustained MRSA bacteremia
Source: Harrison's Principles of Internal Medicine 22E (2025) - MRSA bacteremia recommends vancomycin 15-20 mg/kg IV q8-12h with AUC-guided dosing; daptomycin is the alternative. Intraventricular vancomycin is the approach for device-related CNS MRSA per neurosurgical infection guidelines.
Bottom line: Vancomycin IV is the antibiotic of choice here - it is both culture-directed (Highly Susceptible) and the evidence-based first-line drug for MRSA bacteremia in a neurosurgical/EVD patient. Given the EVD, actively look for ventriculitis and be ready to add intraventricular vancomycin if CSF is involved.
Inj penicillin is inj piptaz 4.5 gm
You're clarifying that the "Penicillin" listed under Resistant on the culture report actually refers to Piperacillin-Tazobactam (Pip-Taz / Piptaz 4.5g).
This is an important point. Here's the updated interpretation:
Revised Sensitivity Interpretation
| Category | Drugs |
|---|---|
| Highly Susceptible | Vancomycin, Moxifloxacin |
| Intermediate | Ciprofloxacin, Levofloxacin, Gentamicin |
| Resistant | Pip-Taz (Piptaz 4.5g), Cefoxitin, Amoxicillin-clavulanate, Erythromycin, Clindamycin, Linezolid |
Clinical Implication
This does not change the recommendation - it actually reinforces it:
- MRSA is inherently resistant to all beta-lactams including Piperacillin-Tazobactam. This is expected and confirms the isolate is truly MRSA.
- Piptaz resistance here is predictable - MRSA produces altered PBP2a (via mecA gene), which has low affinity for ALL penicillins and beta-lactam combinations, so Pip-Taz, Amoxicillin-clavulanate, and Cefoxitin resistance are all consistent findings.
- Do NOT use Piptaz for this patient's MRSA infection regardless of the dose.
Recommendation Remains:
Vancomycin IV - Drug of Choice
- 15-20 mg/kg IV every 8-12 hours
- AUC-guided dosing (target AUC/MIC >400)
- Monitor renal function and drug levels
The only drugs active against this isolate from the report are Vancomycin (first line, IV, for bacteremia) and Moxifloxacin (oral, useful as step-down or adjunct with good CNS penetration).
Piptaz has no role here - this MRSA strain is resistant to it by mechanism, not just by testing.
This is a shared conversation. Sign in to Orris to start your own chat.